diabetes
High Strength, Fixed Combination and Biosimilar Insulin Products: Minimising the Risk of Medication Error
A new document has been posted on the NECS MO website.
High Strength, Fixed Combination and Biosimilar Insulin Products: Minimising the Risk of Medication Error. This is a briefing document which summarises the current guidance and recommendations on ways to minimise the risk of medication errors with newer insulin preparations.
New NICE Guidance on Type 2 Diabetes
A new NICE guideline ‘Type 2 diabetes in adults: management’ is now available. It covers the care and management of type 2 diabetes in adults (aged 18 and over) focusing on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
Use of Abasaglar (Biosimilar Insulin Glargine)
The patent for Lantus® (Insulin glargine) has expired and a biosimilar preparation called Abasaglar®, which has a lower cost, has been launched. It has yet to be considered in the Local medicines decision making process, guidance for use with defined patient criteria is pending.